Adverse effects of tenofovir use in HIV-infected pregnant women and their infants

Keyphrases

• 12-month Follow-up 10%
• Adverse Effects 100%
• Adverse Events 10%
• Anemia 10%
• At Birth 10%
• Birth Weight 10%
• Childhood Growth 10%
• Clinical Data 10%
• Congenital Malformations 10%
• Day Range 10%
• During Pregnancy 20%
• Glomerular Filtration Rate 10%
• Growth Parameters 10%
• Hemoglobin Anomalies 10%
• Highly Active Antiretroviral Therapy (HAART) 30%
• HIV in Pregnancy 100%
• HIV Patients 30%
• Laboratory Results 10%
• Limited Treatment Options 10%
• Median Range 10%
• Modification of Diet in Renal Disease Equation 10%
• Mother-to-child Transmission 10%
• Normal Development 10%
• Normal Growth 10%
• Pregnant Women 10%
• Retrospective Case Series 10%
• Spontaneous Preterm Birth (sPTB) 10%
• Successful Delivery 10%
• Tenofovir 100%
• Tenofovir Disoproxil Fumarate 10%

Medicine and Dentistry

• Abnormal Laboratory Result 10%
• Adverse Effect 100%
• Adverse Event 10%
• Anemia 10%
• Birth Weight 10%
• Congenital Malformation 10%
• Glomerular Filtration Rate 10%
• Growth, Development and Aging 10%
• Hemoglobinopathy 10%
• Highly Active Antiretroviral Therapy 30%
• Human Immunodeficiency Virus 100%
• Nephropathy 10%
• Pregnant Woman 100%
• Prospective Study 10%
• Spontaneous Abortion 10%
• Tenofovir 100%
• Tenofovir Disoproxil 10%
• Treatment Option 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 10%
• Anemia 10%
• Congenital Malformation 10%
• Hemoglobinopathy 10%
• HIV 100%
• Kidney Disease 10%
• Prospective Study 10%
• Spontaneous Abortion 10%
• Tenofovir 100%
• Tenofovir Disoproxil 10%